Medications for Treatment of Opioid Use Disorder among Persons Living with HIV

Extended-release naltrexone improves viral suppression levels in prisoners with HIV and alcohol use disorders who are transitioning to the community

(2018) Sandra A. Springer et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community

(2018) Sandra A. Springer et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder

(2018) Michelle R. Lofwall et al.   JAMA Internal Medicine

Methadone Metabolism And Drug-Drug Interactions: In Vitro And In Vivo Literature Review

(2018) Donna A. Volpe et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies

(2017) Luis Sordo et al.   BMJ-British Medical Journal

Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies

(2017) Luis Sordo et al.   BMJ-British Medical Journal

Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence

(2017) Lars Tanum et al.   JAMA Psychiatry

Adopting the ‘cascade of care’ framework: an opportunity to close the implementation gap in addiction care?

(2016) M. Eugenia Socías et al.   ADDICTION

Primary Care–Based Models for the Treatment of Opioid Use Disorder

(2016) P. Todd Korthuis et al.   ANNALS OF INTERNAL MEDICINE

Impact of Opioid Substitution Therapy on Antiretroviral Therapy Outcomes: A Systematic Review and Meta-Analysis

(2016) Andrea J. Low et al.   CLINICAL INFECTIOUS DISEASES

County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States

(2016) Michelle M. Van Handel et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine

(2016) Richard N. Rosenthal et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis

(2015) Pouya Azar et al.   BMC INFECTIOUS DISEASES

Threading the Needle — How to Stop the HIV Outbreak in Rural Indiana

(2015) Steffanie A. Strathdee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatic Safety of Injectable Extended-Release Naltrexone in Patients With Chronic Hepatitis C and HIV Infection

(2015) Mack C. Mitchell et al.   Journal of Studies on Alcohol and Drugs

Buprenorphine/Naloxone and Methadone Maintenance Treatment Outcomes for Opioid Analgesic, Heroin, and Combined Users: Findings From Starting Treatment With Agonist Replacement Therapies (START)

(2015) Jennifer S. Potter et al.   Journal of Studies on Alcohol and Drugs

Clinic-Based Treatment of Opioid-Dependent HIV-Infected Patients Versus Referral to an Opioid Treatment Program

(2013) Gregory M. Lucas   ANNALS OF INTERNAL MEDICINE

Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners

(2012) Sandra A. Springer et al.   PLoS One

Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis

(2012) G. J. MacArthur et al.   BMJ-British Medical Journal

Hepatic Safety and Antiretroviral Effectiveness in HIV-Infected Patients Receiving Naltrexone

(2011) Jeanette M. Tetrault et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

The Spectrum of Engagement in HIV Care and its Relevance to Test-and-Treat Strategies for Prevention of HIV Infection

(2011) E. M. Gardner et al.   CLINICAL INFECTIOUS DISEASES

Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine

(2011) P Todd Korthuis et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Drug Treatment Outcomes Among HIV-Infected Opioid-Dependent Patients Receiving Buprenorphine/Naloxone

(2011) David A Fiellin et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Improved Quality of Life for Opioid-Dependent Patients Receiving Buprenorphine Treatment in HIV Clinics

(2011) P Todd Korthuis et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study

(2011) Frederick L Altice et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial

(2011) Evgeny Krupitsky et al.   LANCET

Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence

(2011) Ali S. Saber-Tehrani et al.   AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE

Improved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment

(2010) Sandra Ann Springer et al.   JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE

Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review

(2008) Bradley M Mathers et al.   LANCET